Cerity Partners LLC Has $33.18 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Cerity Partners LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 270,326 shares of the biopharmaceutical company’s stock after buying an additional 19,673 shares during the period. Cerity Partners LLC’s holdings in Gilead Sciences were worth $33,182,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. LPL Financial LLC raised its holdings in shares of Gilead Sciences by 4.4% during the 4th quarter. LPL Financial LLC now owns 1,082,514 shares of the biopharmaceutical company’s stock worth $132,868,000 after buying an additional 45,512 shares in the last quarter. Erste Asset Management GmbH raised its holdings in shares of Gilead Sciences by 6.2% during the 4th quarter. Erste Asset Management GmbH now owns 474,467 shares of the biopharmaceutical company’s stock worth $59,203,000 after buying an additional 27,625 shares in the last quarter. Brandywine Global Investment Management LLC raised its holdings in shares of Gilead Sciences by 22.5% during the 4th quarter. Brandywine Global Investment Management LLC now owns 861,496 shares of the biopharmaceutical company’s stock worth $105,740,000 after buying an additional 158,393 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Gilead Sciences by 8.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 607,078 shares of the biopharmaceutical company’s stock worth $74,513,000 after buying an additional 49,568 shares in the last quarter. Finally, CenterBook Partners LP acquired a new position in shares of Gilead Sciences during the 4th quarter worth $852,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive Phase 3 results for a once-weekly HIV regimen using islatravir and lenacapavir, a potential advance that could strengthen Gilead’s already important HIV franchise and support long-term revenue growth. Article Title
• Positive Sentiment: Analysts and recent commentary pointed to momentum in Gilead’s HIV portfolio, including strength in Biktarvy and Descovy, as well as improving expectations for Yeztugo and other late-stage pipeline assets. Article Title
• Positive Sentiment: Gilead said topline Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis showed significantly more patients reached key treatment goals, which could broaden the company’s pipeline and add another growth driver. Article Title
• Neutral Sentiment: Gilead presented at the Goldman Sachs Global Healthcare Conference, which likely reinforced management’s pipeline and growth narrative but did not appear to include a major new catalyst. Article Title
• Negative Sentiment: Gilead and Merck also ended a Phase 3 lung cancer study after Trodelvy plus KEYTRUDA failed to deliver a statistically significant improvement, renewing concern around Gilead’s oncology strategy. Article Title
• Negative Sentiment: Biopharma coverage noted that the Trodelvy setback creates risk for one of Gilead’s key cancer programs, even as HIV progress remains the bigger driver for the stock. Article Title

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Mizuho boosted their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Truist Financial reissued a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Trading Down 3.2%

NASDAQ GILD opened at $121.48 on Thursday. The business’s 50-day moving average price is $133.73 and its two-hundred day moving average price is $134.34. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The firm has a market capitalization of $150.83 billion, a PE ratio of 16.55 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $9,047,570 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.